GlassScriptPhysician profile
Eileen M Beale
NPI 1679977276
$4,251.68
in general payments reported to CMS, 2019-2025
19 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $876 · 2023: $827 · 2024: $1,005 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.37 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.62 | 2021-2025 | Airsupra, Tagrisso, Breztri |
| Novo Nordisk INC | $704.60 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $516.30 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $415.31 | 2023-2025 | Otezla, Otezla, Repatha |
| Astellas Pharma US INC | $338.25 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.69 | 2022-2023 | |
| Dexcom, INC. | $199.11 | 2023-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.60 | 2024-2025 | Xifaxan |
| Pfizer INC. | $173.02 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Dynavax Technologies Corporation | $116.50 | 2022 | |
| Exact Sciences Corporation | $116.08 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $115.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.19 | 2025 | |
| Cequr Corporation | $86.29 | 2024 | Cequr Simplicity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.84 | 2025 | Capvaxive |
| Sumitomo Pharma America, INC. | $21.94 | 2025 | Gemtesa |
| Tris Pharma INC | $17.65 | 2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $13.87 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Beale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.